Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 2009

View Archived Issues

Experiments show TGR5 can be targeted with INT-777 for diabetes and obesity

LEO-29102 cream evaluated in healthy and psoriatic subjects in phase I and II trials

Antibacterial agent GSK-1322322 currently evaluated in phase I and II trials by GSK

Preclinical data on novel lysosomotropic cathepsin K inhibitors presented by Medvir

DAS-181 shows potent preclinical activity against H1N1, H5N1 and seasonal influenza virus

New alliance seeks to measure tumor response to protein kinase inhibitors

Sirona Biochem reports test results for sodium/glucose cotransporter inhibitors

Alligator Bioscience enters into antibody research agreement with BioInvent

PTH-CBD fusion protein reduces chemotherapy-induced osteoporosis in mice

ORM-11984 effective in rat models of osteopenia and osteoporosis

Mologen reaches milestone in MGN-1703 clinical cancer study

Chugai files application for approval of Tarceva for pancreatic cancer in Japan

Novel compounds claimed by The Salk Institute for acute neural injury therapy

Casein kinase II inhibitors described by Bristol-Myers Squibb as oncolytics

Sequenom launches SensiGene cystic fibrosis carrier screening test

Dual PDE4 inhibitors and mAChR agonists in early development at GSK

Meridian Bioscience cleared to update the Tru Flu package insert

Phase IIb results reported for GSK-1838262 in neuropathic pain

Panvax H1N1 vaccine approved for use in Australia

Johnson & Johnson and Elan closing transaction for Alzheimer's immunotherapy program

Neogenix obtains IND clearance to commence phase I NPC-1C trials

Karo Bio expands thyroid hormone receptor platform

Incyte reports encouraging topline phase IIb results for INCB-18424 in psoriasis

Rexahn and Teva close a license agreement for RX-3117

Impax reports results of phase II IPX-066 trial in Parkinson's disease

BioCryst awarded grant by Department of Health & Human Services for peramivir

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...